ENPICOM accelerates antibody and vaccine discovery

Viroclinics-DDL, a Contract Research Organisation (CRO) specialising in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have announced the approval of a joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application.

This R&D partnership project combines in vitro diagnostic and high-throughput sequencing expertise of Viroclinics-DDL and in silico bioinformatics and immunomics knowledge of ENPICOM. The companies aim to develop an integrated wet and dry lab BCR repertoire sequencing technology that can be offered as a full-service proposition. BCR receptor identification and quantification can be used for patients monitoring, evaluation of vaccine efficacy, and to improve antibody-based therapeutic development.

“Viroclinics-DDL’s proven ability to perform molecular diagnostic testing at scale provides a tremendous engine to power innovative therapeutics” said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM. “The joint strengths and capabilities of our experienced and well-diversified teams create not only a more complete portfolio of services for our clients; we are confident that our IGX Platform TCR/BCR sequencing analysis and management, combined with Viroclinics-DDL’s diversified portfolio of assay tools, will allow us to expedite discovery and development of new revolutionary therapeutics and vaccines.”

“This is a great example of our mission to drive purposeful innovation” said Desiree van der Kleij, General Manager at Viroclinics-DDL. “The combined expertise of our companies provides an opportunity to extend our service portfolio of tailor-made molecular diagnostic services for our (bio)pharmaceutical customers.”


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free